As per NPPA Order S.O. 5690(E) dated 17 October 2026, the trade margin on 137 non-scheduled anti-cancer medicines is capped at 30%. Hetero’s revised MRPs take effect on 9 November 2026.
Patients and partners with questions about the revised prices are welcome to speak to their doctor, pharmacist or hospital.
Source: NPPA Order S.O. 5690(E), The Gazette of India, 17 October 2026.
ASRA Division by Hetero Healthcare specialises in advanced treatment solutions for rheumatology and autoimmune disorders. The division is dedicated to improving patient outcomes through innovative, evidence-based therapies designed to address a wide range of autoimmune and musculoskeletal conditions.
ASRA offers a comprehensive portfolio of oral and injectable formulations, supporting rheumatologists and orthopaedic specialists in delivering effective, patient-centric care. With a strong commitment to quality, innovation, and clinical excellence, ASRA continues to provide reliable therapeutic solutions that enhance the standard of care for patients.
View by-